Allergan settles Restasis patent suit with InnoPharma, leaving three defendants
Allergan and InnoPharma settled patent litigation over Restasis (cyclosporine ophthalmic emulsion) yesterday, October 12, leaving three defendants still involved in a much publicised case.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
1 September 2016 Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
1 September 2016 Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
1 September 2016 Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.